ELV:NYSEElevance Health, Inc. Analysis

Elevance Health (ELV) is trading at $403.54, comfortably above its 20‑day, 50‑day and 200‑day moving averages of $374.6, $330.6 and $330.9, indicating a strong upward bias. The 14‑day RSI sits at 78, signaling that the stock is technically overbought. A bullish MACD crossover with a modest histogram of 0.83 supports recent momentum, but the decreasing volume trend tempers enthusiasm. The price is flirting with a key resistance around $405, while the nearest support lies near $325. Relative to peers, ELV’s trailing P/E of 17 is well below the industry average of 27, suggesting a valuation discount. However, the discounted cash‑flow model estimates a fair value of $311, implying the market is pricing in a premium of roughly 30%. Analyst consensus remains a Buy with a median price target of $391, still below the current market level.
Q1 2026 results delivered a 2.9% revenue increase to $50.2 B and a non‑GAAP EPS of $12.58, beating estimates by 16.4% and prompting an upward guidance revision. Operating margins have modestly improved to 5.3% and free cash flow remains healthy at $4.3 B, underpinning the 1.75% dividend with a 29% payout ratio. The balance sheet shows $37 B of cash against $31.8 B of debt, yielding a manageable debt‑to‑equity of 72%. Volatility over the past 30 days is elevated at 27.5%, but a beta of 0.44 indicates lower systematic risk than the broader market. Regulatory and sector dynamics present medium‑level risk, while geographic and currency exposures are low. Given the overbought technical stance but solid earnings momentum, a short‑term hold is prudent, with buy recommendations for the medium and long horizons. Investors should monitor volume trends and the upcoming earnings release for potential near‑term price adjustments.